FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease
Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological…
FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease
Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner. The post FDA Approves Ionis Pharma Drug, the First for…
Bringing Ski Patrol Lessons to Healthtech Entrepreneurship
Three things ski patrol can teach about building a business The post Bringing Ski Patrol Lessons to Healthtech Entrepreneurship appeared first on MedCity News.
Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem
Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs. The post Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem appeared first on MedCity News.
7 Hospital Mergers from Summer 2026
A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health The post 7 Hospital Mergers from Summer 2026 appeared first on MedCity News.
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder
Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed…
Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands
This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture. The post Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands appeared first on MedCity News.
This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication
Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S. The post This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication appeared…
Thyme Care Raises $125M, Launches New Oncology Parent Entity
Thyme Care’s Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The post Thyme Care Raises $125M, Launches New Oncology Parent Entity appeared first on MedCity News.
Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial
In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one….
Automation Didn’t Dehumanize Care. Bad Systems Did.
[Sponsored] We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. The post Automation Didn’t Dehumanize Care. Bad Systems Did. appeared first on MedCity News.
